Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 downregulation inhibits cell proliferation and migration and promotes cell apoptosis in TC. (A and B) RT-qPCR and western bolting were used to determine the expression of PRMT1 in 8505C cells following various treatments. (C and D) CCK-8 and colony formation assays were used to assess cell viability and proliferation, respectively, of treated 8050C cells. (E) Flow cytometry was used to determine apoptosis of treated 8505C cells. (F and G) Wound healing (magnification, ×100) and Transwell (magnification, ×200) assays were used to assess cell migration of the treated 8505C cells. *P<0.05, **P<0.01 vs. si-NC; # P<0.05, ## P<0.01 vs. si-PRMT1; ^^ P<0.01 vs. 10 µM AMI-1. PRMT1, protein arginine methyltransferase 1; TC, thyroid carcinoma; si-NC, small interfering RNA negative control.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 μM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Migration, Quantitative RT-PCR, Western Blot, Expressing, CCK-8 Assay, Colony Assay, Flow Cytometry, Small Interfering RNA, Negative Control, Real-time Polymerase Chain Reaction, Knockdown

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 knockdown suppresses cell metastasis and downregulates expression of ZEB1 and H4R3me2as in TC. (A) IF analyzed the contents of E-cadherin and vimentin in 8505C cells, magnification=400×. (B) Western blotting was used to assess the protein expression levels of E-cadherin, vimentin, H4R3me2as, and ZEB1 in 8505C cells. The 8505C cells were transfected with si-NC or si-PRMT1. *P<0.05, **P<0.01 compared with si-NC; ## P<0.01 compared with si-PRMT1; ^^ P<0.01 compared with 10 µM AMI-1. Each experiment was conducted at least thrice. PRMT1, protein arginine methyltransferase 1; ZEB1, zinc finger e-box binding homeobox1, H4R3me2as, asymmetric demethylation of H4 at the third arginine residue; TC, thyroid carcinoma; si-NC, small interfering RNA negative control.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 μM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Knockdown, Expressing, Western Blot, Transfection, Binding Assay, Residue, Small Interfering RNA, Negative Control, Immunofluorescence

Journal: Oncology Reports

Article Title: PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma

doi: 10.3892/or.2023.8647

Figure Lengend Snippet: PRMT1 knockdown reduces tumor growth and metastasis by inhibiting ZEB1/H4R3me2as in a xenograft model. (A) PRMT1 protein expression in TC tissues (B) Excised tumors from the mouse model of TC. (C) H&E staining of TC tissues. Magnification, ×200. (D) Image of pulmonary nodules and number of pulmonary nodules. (E) TUNEL assays were used to assess apoptosis in xenograft model mice. Magnification, ×400. (F) Western blotting was to measure the protein expression levels of E-cadherin, vimentin, H4R3me2as, and ZEB1 in TC tissues. BALB/C nude mice were subcutaneously injected with treated 8505C cells. *P<0.05, **P<0.01 vs. si-NC; # P<0.05, ## P<0.01 vs. si-PRMT1; ^ P<0.05; ^^ P<0.01 vs. 10 µM AMI-1. PRMT1, protein arginine methyltransferase 1; ZEB1, zinc finger e-box binding homeobox1; H4R3me2as, asymmetric demethylation of H4 at the third arginine residue; TC, thyroid carcinoma; si-NC, small interfering RNA negative control.

Article Snippet: Cells transfected with si-PRMT1 were then treated with 10 or 50 μM AMI-1 (a PRMT1 inhibitor; T2352; TargetMol) for 48 h, or otherwise untreated and used as control cells.

Techniques: Knockdown, Xenograft Assay, Expressing, Staining, TUNEL Assay, Western Blot, Injection, Binding Assay, Residue, Small Interfering RNA, Negative Control, Immunofluorescence